Last updated: June 13, 2024
Sponsor: University of Chile
Overall Status: Active - Recruiting
Phase
2
Condition
N/ATreatment
Nicotinamide
Placebo
Clinical Study ID
NCT06465602
FONDAP 15150012 GERO
Ages > 65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Aged 65 years or older
Living in the community
Increased risk of falls, defined as:
More than two falls in the last 12 months or
Altered balance test (unable to maintain unipedal stance > 5 seconds) or
SPPB score less than 10 points
Exclusion
Exclusion Criteria:
Known Muscle Disease (dystrophy, myopathy, or similar)
Motor sequelae of stroke
Joint pathology with severe pain preventing strength exercises
Cognitive impairment that renders the informed consent process impossible.
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Nicotinamide
Phase: 2
Study Start date:
May 21, 2024
Estimated Completion Date:
February 28, 2025
Study Description
Connect with a study center
Hospital Clínico Universidad de Chile
Santiago,
ChileActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.